Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men in Germany alone are diagnosed with the disease.
Although many patients can be treated successfully when the cancer is found early, prostate cancer can become far more dangerous once it spreads beyond the prostate gland.
When prostate cancer spreads to other parts of the body, doctors call it metastatic prostate cancer. At this stage, the disease is much harder to treat and is linked to higher illness and death rates.
Tumors may grow into nearby tissues or travel through the bloodstream to other organs, forming secondary tumors called metastases. Bones are one of the most common places where prostate cancer spreads.
Doctors currently use treatments such as hormone therapy, radiation therapy, or combinations of therapies to slow the disease. However, patients often respond very differently to these treatments.
Some tumors shrink or remain stable for long periods, while others continue to grow despite treatment. One of the major challenges doctors face is the lack of reliable markers that can predict how aggressive a tumor will be or how well a patient will respond to therapy.
Researchers have therefore been searching for biological markers, also known as biomarkers, that can help doctors better understand how a patient’s cancer will behave.
Biomarkers are measurable substances in the body that provide information about a disease. Some biomarkers can be detected in tissue samples, while others can be measured in blood tests.
A research team led by Professor Anna Dubrovska and Dr. Ielizaveta Gorodetska from OncoRay – National Center for Radiation Research in Oncology in Germany has now discovered a promising new biomarker that may help solve this problem. Their findings were published in the scientific journal Journal of Experimental & Clinical Cancer Research.
The scientists focused on a protein called MMP11, short for matrix metalloproteinase 11. Proteins in this family are known to play roles in how cells move, grow, and interact with surrounding tissues. In cancer, some of these proteins can help tumor cells invade nearby tissue and spread to other parts of the body.
What makes MMP11 particularly interesting is that it can be detected in blood plasma. This means it could potentially be measured through a simple blood test rather than an invasive biopsy.
The study builds on earlier research by Dubrovska’s team. In previous studies, the researchers investigated two enzymes called ALDH1A1 and ALDH1A3. These enzymes belong to a group known as aldehyde dehydrogenases, which help regulate important metabolic processes in the body.
Their earlier work showed that these ALDH genes influence how prostate cancer cells survive in the bloodstream and how they spread to other organs. The genes were also linked to how resistant tumors are to radiation therapy and how likely they are to form bone metastases.
In the new study, the researchers investigated how these ALDH proteins influence other molecules inside cancer cells. Dr. Gorodetska analyzed the molecular signaling pathway involved in this process.
The team discovered that ALDH proteins regulate another signaling molecule known as TGFB1, or transforming growth factor beta 1. This molecule controls the activity of several other proteins involved in tumor growth, including MMP11.
Together, these molecules form a signaling chain that can make tumor cells more aggressive. When this pathway becomes highly active, cancer cells are more likely to invade surrounding tissues and spread throughout the body.
To test the clinical importance of MMP11, the scientists analyzed several large patient datasets. They found that high levels of MMP11 gene activity were strongly linked with advanced and high-risk prostate cancer.
The team then examined blood samples from prostate cancer patients and measured the amount of MMP11 protein present in their blood plasma. The results confirmed that patients with higher levels of MMP11 in their blood were more likely to have metastatic disease and poorer outcomes, especially when treated with radiation therapy.
These findings suggest that MMP11 could become a powerful biomarker for identifying aggressive prostate cancer.
In the future, doctors may be able to use a simple blood test to measure MMP11 levels and determine how aggressive a patient’s cancer is likely to be. Such a test could help doctors detect dangerous disease earlier, choose the most appropriate treatment, and monitor how well therapy is working over time.
Another important advantage of this approach is that blood tests are minimally invasive. Unlike tissue biopsies, which require removing a small piece of tumor tissue, blood tests can be performed quickly and repeatedly. This makes it easier to track changes in the disease during treatment.
According to Professor Dubrovska, this biomarker could help doctors make more personalized treatment decisions. Instead of using the same treatment approach for all patients, doctors could adjust therapies based on the biological behavior of each patient’s tumor.
However, the researchers caution that more work is needed before the test can be used in everyday clinical practice. Developing and approving new medical tests often takes several years. Scientists must confirm the results in larger patient groups and ensure that the test works reliably in different populations.
The research team has already taken an important next step. They are collaborating with the Maria Sklodowska-Curie National Research Institute of Oncology in Poland to further validate MMP11 using multiple independent groups of patients in Germany and Poland.
When analyzing these findings, it becomes clear that this discovery represents a promising step toward more precise cancer diagnosis and treatment. By understanding the molecular signals that drive tumor aggressiveness, researchers can develop better tools to identify high-risk patients earlier.
At the same time, it is important to recognize the limitations of the current study. Although the association between MMP11 and aggressive cancer is strong, further research is needed to determine how accurately the biomarker predicts treatment response in real clinical settings. Large clinical trials will be required to confirm its usefulness.
Nevertheless, the study highlights the growing importance of personalized medicine in cancer care. Instead of treating all cancers the same way, doctors are increasingly using molecular information to guide treatment decisions. Biomarkers like MMP11 could play a key role in this shift by helping doctors tailor therapies to each patient’s unique disease.
If future research confirms these results, a simple blood test measuring MMP11 could become an important tool for improving the diagnosis, monitoring, and treatment of prostate cancer.
If you care about prostate cancer, please read studies about a natural ally against prostate cancer, and supplements and keto diet can boost immunotherapy for prostate cancer.
For more health information, please see recent studies about how to harness the power of anti-cancer foods and supplements, and low-fat diet may help stop cancer growth.
Copyright © 2026 Knowridge Science Report. All rights reserved.
